News - Pharmaceuticals
MA’s growing concern for Australia’s post COVID-19 health hangover

Pharma News: Medicines Australia welcomes the announcement by Prime Minister the Hon Scott Morrison that elective surgery will “gradually restart” but urges increased concurrent attention on Australia’s chronic health care needs to help reduce a significant post COVID-19 health hangover.
Medicines Australia CEO Elizabeth de Somer said “While elective surgery is extremely important, we have seen a marked drop-off in pathology testing and GP visits as a result of COVID-19. The pathology sector alone has seen a 40% drop in routine pathology testing in recent weeks, meaning over 60,000 Australians every day are not getting the tests they need.”
“Not maintaining the nation’s regular health priorities may have catastrophic consequences – for instance taking backward steps in managing diseases like diabetes, or the difference between a stage two and stage four cancer diagnosis.
Register FREE and join 22,000+ industry professionals receiving the latest industry news and engaging content from Health Industry Hub, the ONLY one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals.
“Hospitals, GPs and pathology centres are well equipped to comply with the rigorous COVID-19 hygiene practices and telehealth measures are actively in place. I strongly urge patients and carers to continue with their regular consultations, tests and care arrangements – so we don’t generate a significant back-log as our social distancing measures are relaxed,” she said.
The decision by the National Cabinet on elective surgery will see restrictions eased on about 25% of activity in elective surgery in private and public hospitals.
The pharmaceutical industry stands ready to support hospitals and healthcare workers as they recommence elective surgeries.
“Pharmaceutical manufacturers have worked with wholesalers, hospitals and the Federal Government to ensure there are supplies of medicines and products needed for surgery as it recommences,” said Ms de Somer.
“This includes increasing the supply of critical care medicines and protective equipment for hospital workers as well as diagnostics and devices like ventilators.
“As an industry we have also been working very closely with patient groups on ways to best communicate the importance of maintaining continuity of care.
“Right now, we need to ensure Australians are as healthy as possible with this challenging backdrop in order to lessen the effects of COVID-19 and to minimise the future long-term health hangover that will impact our hospital and healthcare system potentially slowing down our recovery,” concluded Ms de Somer.
HCP engagement during COVID-19. Fill the gap of reduced field force activities. Health Industry Hub combines expertise in delivering digital health content with high engagement and 20+ years industry experience. Created by industry for industry. Contact us.
Digital & Innovation
Health sector faces new privacy obligations
Healthcare organisations must update their privacy policies by 10 December if they use artificial intelligence (AI) or a computer program […]
MoreNews - Pharmaceuticals
TGA approves new antibiotic but AMR blind spot remains a critical concern
The Therapeutic Goods Administration (TGA) has approved a new antibiotic for the treatment of carbapenem-resistant Gram-negative bacterial infections. Developed by […]
MoreNews - MedTech & Diagnostics
BCAL Diagnostics rejects merger speculation
ASX-listed BCAL Diagnostics has moved to quash speculation of a potential three-way merger involving Genetic Signatures and Microba Life Sciences, […]
MoreNews - Pharmaceuticals
Australia backs infectious disease innovation as US funding faces more cuts
Biointelect Venturer, a national incubator supporting infectious disease innovation, will open its second funding round later this month, with AUD […]
More